Replies to post #126415 on Biotech Values

[NP1986]

Wouldn't you think that the Rida results, while not spectacular, are probably good enough for approval?

I think if Tarceva received approval for maintenance therapy in NSCLC based on a modest improvement in outcomes, then ridaforolimus should be approved for sarcoma.

Nevertheless, I've mentioned on the ARIA board before that I am nervous about its approval chances. I'm not excited about ridaforolimus' commercial potential for sarcoma either. Ponatinib is undoubtedly ARIA's crown jewel. For me, any success with ridaforolimus would be a bonus.